- Home
- CET vs AGIO Comparison
CET vs AGIO Comparison
Compare CET & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- AGIO
- Stock Information
- Founded
- CET 1929
- AGIO 2007
- Country
- CET United States
- AGIO United States
- Employees
- CET N/A
- AGIO N/A
- Industry
- CET Finance/Investors Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- AGIO Health Care
- Exchange
- CET Nasdaq
- AGIO Nasdaq
- Market Cap
- CET 1.4B
- AGIO 1.4B
- IPO Year
- CET N/A
- AGIO 2013
- Fundamental
- Price
- CET $49.99
- AGIO $36.20
- Analyst Decision
- CET
- AGIO Buy
- Analyst Count
- CET 0
- AGIO 6
- Target Price
- CET N/A
- AGIO $57.40
- AVG Volume (30 Days)
- CET 14.7K
- AGIO 1.0M
- Earning Date
- CET 01-01-0001
- AGIO 07-31-2025
- Dividend Yield
- CET 4.54%
- AGIO N/A
- EPS Growth
- CET N/A
- AGIO N/A
- EPS
- CET 7.40
- AGIO 11.13
- Revenue
- CET $27,062,484.00
- AGIO $40,875,000.00
- Revenue This Year
- CET N/A
- AGIO $18.94
- Revenue Next Year
- CET N/A
- AGIO $201.70
- P/E Ratio
- CET $6.69
- AGIO $3.18
- Revenue Growth
- CET 15.78
- AGIO 30.57
- 52 Week Low
- CET $40.24
- AGIO $23.42
- 52 Week High
- CET $49.97
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CET 69.41
- AGIO 47.09
- Support Level
- CET $48.54
- AGIO $34.71
- Resistance Level
- CET $49.97
- AGIO $36.89
- Average True Range (ATR)
- CET 0.45
- AGIO 2.44
- MACD
- CET 0.11
- AGIO -0.31
- Stochastic Oscillator
- CET 90.95
- AGIO 66.90
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.